MPL and autoimmune thrombocytopenic purpura: Until now, the management of primary ITP has relied on the utilization of a limited number of drugs, mostly steroids, intravenous immunoglobulins (IVIg), rituximab, thrombopoietin receptor agonists (TPO-RAs) and immunosuppressants, or splenectomy [3].